Trial · NCT07400783
TED_ORG: Study on Short Bowel Syndrome
NCT07400783, Not applicable, Recruiting, Meyer Children's Hospital IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TED_ORG: Study on Short Bowel Syndrome. Trials, record NCT07400783. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07400783
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TED_ORG: Study on Short Bowel Syndrome
- NCT number
- NCT07400783
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Meyer Children's Hospital IRCCS
- Conditions
- Short Bowel Syndrome (SBS)
- Interventions
- Teduglutide (ALX-0600), No Treatment Added
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intestinal organoid diameter after in vitro exposure to teduglutide | During in vitro treatment period (up to 7 days) | Quantitative measurement of intestinal organoid diameter assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant. |
| Primary | Crypt-villus-like architecture in intestinal organoids | During in vitro treatment period (up to 7 days) | Quantitative assessment of crypt-villus-like architectural features in patient-derived human intestinal organoids following in vitro exposure to teduglutide, evaluated by image-based morphological analysis and compared with untreated organoids from the same participant. |
| Primary | Organoid shape (sphericity) after in vitro teduglutide treatment | During in vitro treatment period (up to 7 days) | Quantitative measurement of organoid shape, expressed as sphericity index, in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant. |
| Primary | Lumen size in intestinal organoids after in vitro exposure to teduglutide | During in vitro treatment period (up to 7 days) | Quantitative measurement of lumen size assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant. |
| Primary | Intestinal organoid volume after in vitro exposure to teduglutide | During in vitro treatment period (up to 7 days) | Quantitative measurement of intestinal organoid volume assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant. |
| Primary | Lumen integrity in intestinal organoids after in vitro exposure to teduglutide | During in vitro treatment period (up to 7 days) | Quantitative assessment of lumen integrity assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07400783
GET https://conductscience.org/api/trials/v1/NCT07400783/registered